Yang Fan, Meng Ran, Zhu Da-Long
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
Chronic Dis Transl Med. 2020 Aug 15;6(4):239-245. doi: 10.1016/j.cdtm.2020.07.002. eCollection 2020 Dec.
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT2抑制剂）是一种新型的糖尿病治疗药物，已被证明具有良好的降糖效果。多项临床证据表明，SGLT2抑制剂可显著降低动脉粥样硬化、因心力衰竭住院、心血管死亡和全因死亡率的风险，并延缓慢性肾脏病的进展。由于SGLT2抑制剂对心脏和肾脏具有保护作用，目前正在研究其用于治疗非糖尿病患者的心力衰竭和慢性肾脏病。因此，心脏病专家、糖尿病患者和肾脏病专家有必要充分了解这类药物。在本综述中，我们总结了SGLT2抑制剂的以下三个方面：其心血管益处的最新临床证据、作用机制及其安全性。
